SVF
Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Therapeutic role of caveolin family in stem cell fate and development for management of chronic degenerative diseases: A scientometric study to an in-depth review

Ma R., Wang S., Cui YL., Zhang H., Chen X., Xie J.

Narrative Review on Diabetic Foot, Stroke Research, Neuroinflammation, Chronic Wound, published in J Adv Res (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Adv Res (2026)
Reported sample size
—
Source database
Europe PMC
PMID
40554062
PMCID
PMC12957836
DOI
10.1016/j.jare.2025.06.034
Citations
3

Abstract (original English)

Background Caveolins (CAV), a family of integral membrane proteins, are involved in regulating stem cell fate, which are critical for tissue repair and regeneration. Drawing from scientometric studies and comprehensive research, this review investigates the mechanisms by which CAV regulates stem cell fate can improve the efficiency and accuracy of stem cell therapy in treating chronic degenerative diseases (CDD). For instance, CAV1 inhibits neuronal differentiation of neural stem/progenitor cells (NSCs/NPCs) by downregulating VEGF, p44/42MAPK phosphorylation and NeuroD1 signaling pathway following ischemic stroke, while CAV3 interacts with MG53 to enhance the therapeutic effects of bone marrow mesenchymal stem cells (BMSCs) in diabetic wound healing by activating the eNOS/NO signaling pathway. Aim of review Our review aims to elaborate the impact of CAV on diverse stem cell populations and regulatory mechanisms, as well as point out novel insights brought by CAV and stem cell therapy in the management of CDD, such as stroke, Alzheimer's disease (AD), Parkinson's disease (PD), diabetes, pulmonary arterial hypertension (PAH), breast cancer and liver cancer. Key scientific concept of review Based on scientometrics studies, this review synthesizes current analyses of the CAV family's role in determining the fate of various stem cell populations, thereby providing new perspectives f

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Stem CellsAnimalsHumansNeurodegenerative DiseasesChronic DiseaseCaveolinsSignal TransductionCell Differentiation
Systemic / IVDiabetic FootStroke ResearchNeuroinflammationChronic Wound
View on PubMedFull text on Europe PMCDOI

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

View all: topic “therapeutic role caveolin”View all: author maView all: year 2026

Related research